Pronutria, a Cambridge company seeking to develop medical foods and nutritional supplements, said Thursday that it has closed a $12.25 million in Series B financing that will fund the advancement of its pipeline.
Pronutria also said that it is starting two clinical trials that will evaluate its lead ProNutrein product candidates.
According to the company, it is using its “ProNutrein discovery platform to identify and develop protein pharmaconutrients, protein nutrients identified in food with beneficial impact in many areas of human health, including muscle, metabolic, and gastrointestinal health.”
Pronutria was founded in 2011 by Flagship VentureLabs, the innovation foundry of Flagship Ventures. The Series B financing was led by Flagship and included private investors. The company said it has raised $23 million to date.
In a statement, Pronutria chief executive Robert Connelly said, “Pronutria’s world-leading understanding of amino acid pharmacology has positioned us to rapidly build a pipeline of orally administered protein products that can have life changing benefits for millions.’’